Patent: 6,555,518
✉ Email this page to a colleague
Summary for Patent: 6,555,518
Title: | Gemcitabine as an immunosuppressive pharmaceutical agent |
Abstract: | The present invention provides the use of a compound of the formula I ##STR1## wherein: R.sub.1 is a base defined by one of the formulae ##STR2## R.sub.2 is hydrogen, C.sub.1 -C.sub.4 alkyl, bromo, fluoro, chloro or iodo; or a pharmaceutically-acceptable salt thereof for the manufacture of a medicament for immunosuppressive therapy of the human or animal body. |
Inventor(s): | Margreiter; Raimund (Reith b. Seefeld, AT), Konwalinka; Gunther (Innsbruck, AT) |
Assignee: | Eli Lilly and Company (Indianapolis, IN) |
Application Number: | 09/687,565 |
Patent Claims: | see list of patent claims |
Details for Patent 6,555,518
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Hoffmann-la Roche Inc. | ZENAPAX | daclizumab | Injection | 103749 | 12/10/1997 | ⤷ Try a Trial | 2018-04-14 |
Biogen Inc. | ZINBRYTA | daclizumab | Injection | 761029 | 05/27/2016 | ⤷ Try a Trial | 2018-04-14 |
Biogen Inc. | ZINBRYTA | daclizumab | Injection | 761029 | 05/26/2017 | ⤷ Try a Trial | 2018-04-14 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |